Quantcast

Latest Dabigatran Stories

2014-10-15 20:22:42

Company to make OFEV available to IPF community within 10 days, along with comprehensive patient support resources RIDGEFIELD, Conn., Oct. 15, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced that the U.S. Food and Drug Administration (FDA) approved OFEV® (nintedanib) capsules for oral use for the treatment of idiopathic pulmonary fibrosis (IPF). Granted Breakthrough Therapy designation during its review by the FDA, OFEV, capsules for oral use, taken twice...

2014-10-12 23:01:29

The Firm is evaluating potential legal claims on behalf of individuals who allegedly suffered uncontrollable internal bleeding and other serious side effects due to the use of the blood thinning medication. New York, New York (PRWEB) October 12, 2014 Plaintiffs in six Xarelto lawsuits (http://www.xareltolawsuitcenter.com) have asked the U.S. Judicial Panel on Multidistrict Litigation (JPML) to consolidate all pending and future federally-filed product liability claims involving the blood...

2014-10-08 04:21:11

Case Funding Company says recent $650MM settlement of approximately 4K filed cases in both state and federal courts over blood thinner, amounts to an average Pradaxa settlement amount or settlement value of approximately $150K per case. SAN FRANCISCO, Oct. 8, 2014 /PRNewswire/ -- Legal-Bay LLC, the Lawsuit Settlement Funding Company, announced today that they are increasing their pre-settlement and settlement funding amounts on all Pradaxa cases based on the recent settlement by...

2014-09-30 23:24:17

As Pradaxa Lawsuit Claims Continue Boehringer Ingelheim Conducts Clinical Trials On Idarucizumab, A Potential Reversal Agent To Pradaxa Columbus, OH (PRWEB) September 30, 2014 Wright & Schulte LLC has learned that Boehringer Ingelheim Pharmaceuticals, Inc. is testing a possible antidote for Pradaxa, the company’s oral anticoagulant that is the focus of almost 2500 Pradaxa lawsuits pending in the U.S. District Court, Southern District of Illinois alleging uncontrollable bleeding. The...

2014-09-28 23:02:43

Wright & Schulte LLC Continues To Investigate Complaints That Janssen Pharmaceuticals Did Not Disclose The Lack of An Effective Means To Treat Uncontrolled Bleeding In Patients Taking Xarelto Columbus, OH (PRWEB) September 28, 2014 Wright & Schulte LLC has learned that a Xarelto bleeding lawsuit complaint was filed on behalf of a California woman who alleges that she suffered life-threatening bleeding as a result of taking the blood thinner medication. According to the Xarelto...

2014-09-15 08:29:35

-Direct Oral Anticoagulant Measurement, Automated on ACL TOP® Family of Hemostasis Testing Systems- BEDFORD, Mass., Sept. 15, 2014 /PRNewswire/ --Instrumentation Laboratory (IL) today announced the commercialization in Europe of their HemosIL Direct Thrombin Inhibitor (DTI) Assay. When used in conjunction with HemosIL Dabigatran Calibrators and Controls, this test offers an automated solution for the measurement of dabigatran, a direct oral anticoagulant (DOAC). The assay,...

2014-09-02 23:01:40

The Firm is evaluating Xarelto lawsuits on behalf of patients who suffered uncontrollable internal bleeding, stroke, deep vein thrombosis, pulmonary embolism, or death, allegedly due to their use of the blood thinner. New York, NY (PRWEB) September 02, 2014 The use of Xarelto (known generically as rivaroxaban) and other new blood thinners is growing at a rapid pace, even as Xarelto lawsuits (http://www.xareltolawsuitcenter.com) continue to mount in courts around the U.S., Bernstein...

2014-09-02 12:29:39

BARCELONA, Spain, September 2, 2014 /PRNewswire/ -- -- GARFIELD-AF Registry presentations at ESC CONGRESS 2014 provide insight into treatment and outcomes of patients at risk of stroke in everyday clinical practice -- Data from nearly 12,500 patients enrolled in the Global Anticoagulant Registry in the FIELD-Atrial Fibrillation (GARFIELD-AF), an innovative, independent academic research initiative, have illustrated that stroke prevention strategies for atrial...

2014-09-02 08:30:31

Patients at higher risk of kidney problems due to existing diabetes were also evaluated for the effects of warfarin on kidney function RIDGEFIELD, Conn., Sept. 2, 2014 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. today announced results from a new post-hoc sub-analysis of the pivotal phase III RE-LY® trial assessing renal function change in patients with non-valvular atrial fibrillation (NVAF) treated with Pradaxa® (dabigatran etexilate mesylate) compared to warfarin. The...

2014-08-26 23:05:43

Kristine Kraft, partner at Schlichter, Bogard & Denton, LLP, reports on the findings of a new study published in the Journal of Neurosurgery regarding the increased difficulties of stopping bleeding events for patients using certain direct Factor Xa inhibitor medications, including Xarelto®. The attorneys at Schlichter, Bogard & Denton, LLP are offering free and confidential case reviews to those who allege to have suffered serious bleeding events after using Xarelto®....


Word of the Day
reremouse
  • A bat.
The word 'reremouse' comes from Middle English reremous, from Old English hrēremūs, hrērmūs ("bat"), equivalent to rear (“to move, shake, stir”) +‎ mouse.
Related